Testing GDC-0032 (Taselisib) as a Potential Targeted Treatment in Cancers With PIK3CA Genetic Changes (MATCH-Subprotocol I)
Clinical trial NCT04439175 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT04439175
- Sponsor
- National Cancer Institute (NCI)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2016-02-25
- Primary completion
- 2020-11-10
- Enrollment
- 70
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.